Anne Li 6/17/17 For more information please email: email@example.com
Children as young as 8 years old with incurable cancer can reliably characterize the impact an experimental therapy has on their symptoms and quality of life — even at the earliest stages of drug development — making self-reported patient outcomes a potential new clinical trial endpoint, according to a longitudinal validity study led by Children's National Health System researchers. Cancer is the No. 1 disease-related cause of death in U.S. children aged 1 to 19, and roughly 25 percent of the 12,400 children newly diagnosed with cancer will die of their disease, the study authors write.
See original article at: https://www.sciencedaily.com/releases/2017/06/170615120631.htm